+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 55 Pages
  • August 2023
  • GlobalData
  • Medigene
  • ID: 3143820
MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MediGene AG (MediGene) is a biotechnology company which develops innovative immunotherapies to treat cancer with candidates in clinical and pre-clinical development. It focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects; and kills tumor cells and T-cell-specific monoclonal antibodies (TAB's), for isolation of antibodies for monitoring and tracking of TCR-Ts. The company has operational presence in the US and Europe. Medigene is headquartered in Planegg, Germany.

MediGene AG Key Recent Developments

  • Jun 22, 2023: Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
  • Jun 13, 2023: Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors
  • Jun 01, 2023: Medigene Announces Pipeline Expansion Into Neoantigens With Programs Targeting Multiple KRAS Mutations and HLAs
  • May 04, 2023: Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • MediGene AG - Key Facts
  • MediGene AG - Key Employees
  • MediGene AG - Key Employee Biographies
  • MediGene AG - Major Products and Services
  • MediGene AG - History
  • MediGene AG - Company Statement
  • MediGene AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • MediGene AG - Business Description
  • Business Segment: Immunotherapies (core business)
  • Overview
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: The US
  • Performance
  • MediGene AG - Corporate Strategy
  • MediGene AG - SWOT Analysis
  • SWOT Analysis - Overview
  • MediGene AG - Strengths
  • MediGene AG - Weaknesses
  • MediGene AG - Opportunities
  • MediGene AG - Threats
  • MediGene AG - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • MediGene AG, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 22, 2023: Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
  • Jun 13, 2023: Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors
  • Jun 01, 2023: Medigene Announces Pipeline Expansion Into Neoantigens With Programs Targeting Multiple KRAS Mutations and HLAs
  • May 04, 2023: Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment
  • May 03, 2023: Medigene reports financial results and business update for Q1 2023
  • Apr 04, 2023: Medigene AG presents systematic and sequential, end-to-end platform approach to optimize TCR-T therapy development
  • Mar 28, 2023: Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
  • Mar 20, 2023: Medigene AG Announces Appointment of Dr. Kirsty Crame MD as Head of Clinical Research & Development
  • Mar 15, 2023: Medigene to report full year 2022 financial results on March 29, 2023
  • Nov 15, 2022: Medigene Announces Strategy and Corporate Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • MediGene AG, Key Facts
  • MediGene AG, Key Employees
  • MediGene AG, Key Employee Biographies
  • MediGene AG, Major Products and Services
  • MediGene AG, History
  • MediGene AG, Subsidiaries
  • MediGene AG, Key Competitors
  • MediGene AG, Ratios based on current share price
  • MediGene AG, Annual Ratios
  • MediGene AG, Interim Ratios
  • MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • MediGene AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • MediGene AG, Performance Chart (2018 - 2022)
  • MediGene AG, Ratio Charts
  • MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ambrilia Biopharma Inc
  • Tigo GmbH
  • Genentech USA Inc
  • AIM ImmunoTech Inc
  • 4SC AG